Related Experiment Video
Updated: Jun 5, 2026
13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity
1Institute for Cancer Research, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 120-752, Korea.
BMB Reports
|December 30, 2010
Summary
Adenovirus (Ad) vectors show promise for cancer gene therapy but struggle with systemic delivery. New hybrid nanocomplexes improve Ad targeting and efficacy for treating metastatic cancers.
Area of Science:
- Oncolytic virotherapy
- Nanomedicine
- Gene therapy
Background:
- Adenovirus (Ad) vectors are effective for intralesional cancer treatment but face challenges in systemic delivery.
- Conventional Ad administration results in rapid liver accumulation, immune neutralization, and poor targeting of metastatic sites.
Purpose of the Study:
- To review advancements in developing smart Ad hybrid nanocomplexes for improved systemic delivery in cancer gene therapy.
- To explore design strategies enhancing Ad anti-tumor activity and specificity.
Main Methods:
- Review of current literature on modifying adenovirus surfaces with polymers and nanomaterials.
- Analysis of strategies for creating viral-nonviral hybrid nanomaterials for gene therapeutics.
Main Results:
- Surface modification of Ad vectors with polymers and nanomaterials offers versatile strategies for optimizing systemic delivery.
- Integration of viral and non-viral nanomaterials presents novel concepts for gene therapeutics.
Conclusions:
- Smart Ad hybrid nanocomplexes represent a promising approach to overcome limitations of conventional Ad vectors for systemic cancer gene therapy.
- Further development in this area can significantly advance the field of gene therapeutics for metastatic diseases.
